We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $363M
1-Year Est. Return 34.89%
This Fund
S&P 500
This Quarter Est. Return
+6.98%
1 Year Est. Return
+34.89%
3 Year Est. Return
+131.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$368M
AUM Growth
+$18.7M
Cap. Flow
+$14.9M
Cap. Flow %
4.04%
Top 10 Hldgs %
6.4%
Holding
553
New
113
Increased
199
Reduced
149
Closed
92

Top Buys

Rank Stock Value
1
EXPD icon
Expeditors International
EXPD
+$2.17M
2
INCY icon
Incyte
INCY
+$2.09M
3
WAT icon
Waters Corp
WAT
+$2.03M
4
AMAT icon
Applied Materials
AMAT
+$2.01M
5
LVS icon
Las Vegas Sands
LVS
+$2.01M

Top Sells

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$2.5M
2
EA
Electronic Arts
EA
+$2.43M
3
FOXA icon
Fox Class A
FOXA
+$2.05M
4
MS icon
Morgan Stanley
MS
+$2.04M
5
ATO icon
Atmos Energy
ATO
+$2.02M

Sector Composition

Rank Sector Weight
1 Healthcare 26.73%
2 Financials 22.73%
3 Technology 18.16%
4 Industrials 8.89%
5 Consumer Discretionary 7.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGNX icon
276
Regenxbio
RGNX
$708M
$276K 0.08%
19,181
+8,026
+72% +$100K
GPCR icon
277
Structure Therapeutics
GPCR
$3.78B
$276K 0.08%
3,967
-1,154
-23% -$47.1K
PCVX icon
278
Vaxcyte
PCVX
$8.64B
$276K 0.08%
5,979
+2,677
+81% +$120K
RCKT icon
279
Rocket Pharmaceuticals
RCKT
$394M
$275K 0.07%
78,474
+41,410
+112% +$142K
ZYME icon
280
Zymeworks
ZYME
$1.67B
$275K 0.07%
10,441
+1,755
+20% +$38.3K
ERAS icon
281
Erasca
ERAS
$6.39B
$275K 0.07%
73,896
-475
-0.6% -$1.34K
LQDA icon
282
Liquidia Corp
LQDA
$8.02B
$275K 0.07%
7,969
+95
+1% +$2.7K
JBIO
283
Jade Biosciences
JBIO
$1.34B
$274K 0.07%
+17,759
New +$208K
WVE icon
284
Wave Life Sciences
WVE
$1.2B
$273K 0.07%
16,064
+260
+2% +$2.64K
CMPS
285
Compass Pathways
CMPS
$1.83B
$272K 0.07%
39,471
+14,297
+57% +$87.2K
ABUS icon
286
Arbutus Biopharma
ABUS
$915M
$272K 0.07%
56,483
+24,699
+78% +$111K
XENE icon
287
Xenon Pharmaceuticals
XENE
$6.12B
$271K 0.07%
6,037
+2,568
+74% +$108K
VERA icon
288
Vera Therapeutics
VERA
$2.36B
$271K 0.07%
5,342
+290
+6% +$10.3K
CTMX icon
289
CytomX Therapeutics
CTMX
$754M
$270K 0.07%
+63,491
New +$241K
LXEO icon
290
Lexeo Therapeutics
LXEO
$378M
$270K 0.07%
+27,230
New +$248K
IDYA icon
291
IDEAYA Biosciences
IDYA
$3.56B
$270K 0.07%
7,819
+2,712
+53% +$86.5K
DYN icon
292
Dyne Therapeutics
DYN
$4.9B
$270K 0.07%
13,806
+5,937
+75% +$112K
CYTK icon
293
Cytokinetics
CYTK
$10.4B
$270K 0.07%
4,247
+819
+24% +$50.9K
CGON icon
294
CG Oncology
CGON
$6.66B
$270K 0.07%
6,497
+2,203
+51% +$91.2K
PROK icon
295
ProKidney
PROK
$337M
$270K 0.07%
+120,376
New +$317K
BEAM icon
296
Beam Therapeutics
BEAM
$2.84B
$270K 0.07%
9,724
+3,200
+49% +$81.6K
ANNX icon
297
Annexon
ANNX
$886M
$269K 0.07%
53,527
+11,540
+27% +$44.1K
RVMD icon
298
Revolution Medicines
RVMD
$44B
$269K 0.07%
3,371
+603
+22% +$39.5K
ORKA
299
Oruka Therapeutics
ORKA
$5.96B
$267K 0.07%
+8,814
New +$246K
RAPP
300
Rapport Therapeutics
RAPP
$2.18B
$267K 0.07%
8,789
-1,425
-14% -$39.4K
10 11
12
13 14

Similar funds

RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
HS
HighVista Strategies Boston, Massachusetts $362M AUM 230.96% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

Virtus Investment Advisers's Q4 2025 Portfolio in Review

As of Q4 2025, Virtus Investment Advisers held 553 positions worth $368M, up 5.3% from $349M the previous quarter. Its ten largest holdings account for 6.4% of the portfolio.

Virtus Investment Advisers deployed $14.9M of net new capital in Q4 2025, opening 113 new positions and adding to 199 existing holdings. Its largest new stake was Expeditors International: 15,974 shares worth $2.38M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, up from 17% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was VICI Properties, an estimated $1.66M trimmed.

  • Virtus Investment Advisers's largest Q4 2025 buy was Expeditors International: 15,974 shares worth $2.38M.
  • Virtus Investment Advisers added most to Incyte in Q4 2025, an estimated $2.09M increase.
  • Virtus Investment Advisers's biggest Q4 2025 reduction was VICI Properties, cutting an estimated $1.66M.
  • Virtus Investment Advisers fully exited Tesla in Q4 2025, selling an estimated $2.5M.
  • Virtus Investment Advisers's ten largest holdings make up 6.4% of its $368M portfolio in Q4 2025.
  • Virtus Investment Advisers opened 113 new positions and closed 92 in Q4 2025.
  • Virtus Investment Advisers's portfolio value rose 5.3% quarter-over-quarter to $368M.

Based on Virtus Investment Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.